Find Ruzasvir manufacturers, exporters & distributors on PharmaCompass

Ruzasvir

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

18 Intermediates Suppliers

18 Intermediates Suppliers

DIGITAL CONTENT

4 NEWS #PharmaBuzz

media
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1613081-64-3, Mk-8408, Lx752bd95y, Carbamic acid, n,n'-(((6s)-6-(2-cyclopropyl-5-thiazolyl)-1-fluoro-6h-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, c,c'-dimethyl ester, Methyl n-[(2s)-1-[(2s)-2-[5-[(6s)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-6h-indolo[1,2-c][1,3]benzoxazin-10-yl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate, Ruzasvir [usan:inn]

Molecular Formula

C₄₉H₅₅FN₁₀O₇S

Molecular Weight

947.1 g/mol

InChI Key

AXWDHVUJXNOWCC-RAEGKSCOSA-N

FDA UNII

LX752BD95Y

Ruzasvir has been used in trials studying the treatment of Hepatitis C, Hepatitis C, Chronic, and Hepatitis C Infection.

1 2D Structure

Ruzasvir

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

2.1.2 InChI

InChI=1S/C49H55FN10O7S/c1-24(2)40(56-48(63)65-5)45(61)58-15-7-9-34(58)42-51-21-31(54-42)27-13-14-33-29(17-27)19-36-39-30(50)18-28(20-37(39)67-47(60(33)36)38-23-53-44(68-38)26-11-12-26)32-22-52-43(55-32)35-10-8-16-59(35)46(62)41(25(3)4)57-49(64)66-6/h13-14,17-26,34-35,40-41,47H,7-12,15-16H2,1-6H3,(H,51,54)(H,52,55)(H,56,63)(H,57,64)/t34-,35-,40-,41-,47-/m0/s1

2.1.3 InChI Key

AXWDHVUJXNOWCC-RAEGKSCOSA-N

2.1.4 Canonical SMILES

CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C(=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)F)C9=CN=C(S9)C1CC1)NC(=O)OC

2.1.5 Isomeric SMILES

CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C(=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)F)C9=CN=C(S9)C1CC1)NC(=O)OC

2.2 Other Identifiers

2.2.1 UNII

LX752BD95Y

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Mk-8408

2.3.2 Depositor-Supplied Synonyms

1. 1613081-64-3

2. Mk-8408

3. Lx752bd95y

4. Carbamic Acid, N,n'-(((6s)-6-(2-cyclopropyl-5-thiazolyl)-1-fluoro-6h-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,c'-dimethyl Ester

5. Methyl N-[(2s)-1-[(2s)-2-[5-[(6s)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-6h-indolo[1,2-c][1,3]benzoxazin-10-yl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

6. Ruzasvir [usan:inn]

7. Unii-lx752bd95y

8. Ruzasvir [usan]

9. Ruzasvir (usan/inn)

10. Ruzasvir [inn]

11. Ruzasvir [who-dd]

12. Chembl3971095

13. Schembl18268432

14. Db11713

15. J3.601.978f

16. D11217

17. Q27283234

18. Dimethyl ((2s,2's)-((2s,2's)-(((s)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6h-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate

2.4 Create Date

2015-10-16

3 Chemical and Physical Properties

Molecular Formula	C₄₉H₅₅FN₁₀O₇S
Molecular Weight	947.1 g/mol
XLogP3	6.4
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	14
Exact Mass	946.39599347 g/mol
Monoisotopic Mass	946.39599347 g/mol
Topological Polar Surface Area	230 Å²
Heavy Atom Count	68
Formal Charge	0
Complexity	1840
Isotope Atom Count	0
Defined Atom Stereocenter Count	5
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)

Drugs in Development